There is a lot, and I mean a lot, of discussion right now about the potential for artificial intelligence (AI) to transform the pharmaceutical industry (as, indeed, there is across all industries).

Using artificial intelligence-powered software for screening electrocardiograms (ECGs) could deliver results more quickly and allow treatment to be started earlier, according to a new study.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

There’s a tendency to overlook the fact that human health and animal health are closely intertwined. As an Ethnozoology published paper put it, “we share hundreds of diseases with animals, and ...

Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the ...

April was both National Minority Health Month and Counselling Awareness Month, designations that call attention to persistent health disparities among racial and ethnic minorities and lift up the ...

To encourage the uptake of complex therapies in clinical practice, brand teams must ensure they use data-driven insights to understand the needs and preferences of healthcare professionals (HCPs ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...

Pharmaceutical companies are eagerly pursuing GenAI products and use cases to generate value within their organisations. Many are heavily investing in consultants to help develop strategies and ...

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myeloma, but new data from the ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ...

Cell therapy is a field rife with innovation, but most of the novel therapies being developed fall into one of two basic categories: autologous cell therapies, which involve removing a patient’s ...